Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Net Sales has grown by an annual rate of 6.03% and Operating profit at -99.94% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.49
2
The company has declared Negative results for the last 4 consecutive quarters
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
PLN 5 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.05
171.51%
-5.34
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Mar 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-33.33%
0%
-33.33%
6 Months
-30.56%
0%
-30.56%
1 Year
-60.63%
0%
-60.63%
2 Years
-65.52%
0%
-65.52%
3 Years
-43.82%
0%
-43.82%
4 Years
-58.33%
0%
-58.33%
5 Years
-61.24%
0%
-61.24%
Telemedycyna Polska SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.03%
EBIT Growth (5y)
-99.94%
EBIT to Interest (avg)
-1.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.11
Sales to Capital Employed (avg)
2.40
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
4.40%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.41
EV to EBIT
-3.62
EV to EBITDA
-4.30
EV to Capital Employed
6.75
EV to Sales
1.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-186.57%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
1.30
1.50
-13.33%
Operating Profit (PBDIT) excl Other Income
-0.30
-0.40
25.00%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-0.40
-0.50
20.00%
Operating Profit Margin (Excl OI)
-309.40%
-323.90%
1.45%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -13.33% vs 7.14% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 20.00% vs 28.57% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5.40
6.10
-11.48%
Operating Profit (PBDIT) excl Other Income
-2.00
-1.00
-100.00%
Interest
0.10
0.10
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-2.70
-0.20
-1,250.00%
Operating Profit Margin (Excl OI)
-415.40%
-203.50%
-21.19%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -11.48% vs -6.15% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -1,250.00% vs 85.71% in Dec 2023
About Telemedycyna Polska SA 
Telemedycyna Polska SA
Pharmaceuticals & Biotechnology
Telemedycyna Polska SA is a Poland-based company engaged in provision of medical services via telephone, the Internet and radio waves. It operates Kardiotele system which enables cardiologic care and checks such as electrocardiogram (EKG) through telephone connection. Kariotele is addressed to individuals, as well as to nursing homes and rehabilitation centers. As of December 31, 2011, the Company operated one wholly owned subsidiary, Centrum Nadzoru Kardiologicznego Kardiofon Sp. z o.o.
Company Coordinates 
Company Details
Ul. Ligocka 103 , KATOWICE None : 40-568
Registrar Details






